131,445 research outputs found
Callen, D W, VX16070
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/375481Surname: CALLEN
Given Name(s) or Initials: D W
Military Service Number or Last Known Location: VX16070
Missing, Wounded and Prisoner of War Enquiry Card Index Number: 7018188182
Item: [2016.0049.07789] "Callen, D W, VX16070
Magnetic anisotropy in the cubic Laves REFe2 intermetallic compounds
No full textIn the past, the Callen–Callen (1965 Phys. Rev. 139 A455–71; 1966 J. Phys. Chem. Solids 27 1271–85) model has been highly successful in explaining the origin and temperature dependence of the magneto-crystalline anisotropy in many magnetic compounds. Yet, despite their high ordering temperatures of ~650 K, the Callen–Callen model has proved insufficient for the REFe2 compounds. In this paper, we show that it is possible to replicate the values of the phenomenological parameters K1, K2, and K3 given by Atzmony and Dariel (1976 Phys. Rev. B 13 4006–14), by extending the Callen–Callen model to second order in HCF. In particular, explanations are provided for (i) the unexpected changes in sign of K1 and K2 in HoFe2 and DyFe2, respectively, and (ii) the origin and behaviour of the K3 term. In addition, it is demonstrated that higher order terms are required, and that K4 exceeds K3 at low temperatures. Revised estimates of K1, K2, K3, K4, and K5 are given. Finally, an alternative 'multipolar' approach to the problem of magnetic anisotropy is also provided. It is shown that the latter confers significant advantages over the older phenomenological method. In particular, all the multipolar coefficients (\tilde {K}_N , N = 4, 6, 8, 10, 12) decrease monotonically with increasing temperature, with \tilde {K}_N decreasing faster than \tilde {K}_{N-2} etc. These observations are in accord with expectations based on the original Callen–Callen model
Craig Callen: Tributes from the Evidence Community
No full textAt the wonderful memorial service for Craig Callen held at MSU shortly after his death in April, I had the honor, by reason of proximity, to appear in effect as the representative of nationwide, and even worldwide, community of scholars that has felt his death very deeply. I am grateful for the opportunity to perform this same function in print
Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity
No full textAccepted 8 June 2017Abstract not availableBeatriz Blanco, Kathryn A. Palasis, Alaknanda Adwal, David F. Callen, Andrew D. Abel
Letter from G. D. Callen to James Dellet in Claiborne, Alabama.
No full textCallen writes regarding two slaves he has hired out to a carpenter in Mobile; Dellet is to be involved in the exchange of the men and money
Tumour Suppressor Gene
No full textPATENT: D. F. Callen, S. A. Whitmore, G. Kremmidiotis, M. Kochetkova, J. Crawford, Joanna (Assignee: Bionomics Ltd). WO 2002/018592 A1 (PCT/AU2001/001097) filed Aug 31, 2001; published Mar 7, 2002.The invention provides an isolated DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or active fragments thereof, which encode a polypeptide active in suppressing cellular functions associated with cancer. In particular, the polypeptide (MTG16) functions as a tumour suppressor gene. It also provides variants of such DNA molecules which retain their function, polypeptides encoded by the DNA molecules and antibodies thereto, as well as the use of these molecules in diagnostic, prognostic and therapeutic procedures and other uses such as screening for candidate pharmaceuticals and animal model generation.Invented by D. F. Callen, S. A. Whitmore, G. Kremmidiotis, M. Kochetkova, J. Crawford, Joanna; Assigned to Bionomics Ltd; Griffith Hack agents for inventors
Tumour Suppressor Gene Identified on Chromosome 18
No full textPATENT: D. F. Callen, S. A. Whitmore, G. Kremmidiotis, M. Kochetkova, J. Crawford (Assignee: Bionomics Ltd). WO 2002/048354 A1 (PCT/AU2001-001623) filed Dec 14, 2001; published Jun 20, 2002.The invention provides an isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1, or active fragment thereof, which encodes a polypeptide active in suppressing cellular proliferation. In particular, TSG18 functions as a tumour suppressor gene as well as having a role in immune/autoimmune/inflammatory disorders. It also provides variants of such DNA molecules which retain their function, polypeptides encoded by the DNA molecules and antibodies thereto, as well as the use of these molecules in diagnostic, prognostic and therapeutic procedures and other uses such as screening for candidate pharmaceuticals.Invented by D. F. Callen, S. A. Whitmore, G. Kremmidiotis, M. Kochetkova, J. Crawford; Assigned to Bionomics Ltd; Griffith Hack agents for inventors
Absence of the Epstein-Barr virus genome in breast cancer-derived cell lines
No full text© 2003 Oxford University PressPeter Speck, David F. Callen, Richard Longnecke
Assignment of the human skeletal muscle a-tropomyosin gene (TPM1) to band 15q22 by fluorescence in situ hybridization
No full textA sequence-tagged site (STS) was developed for the human skeletal muscle α-tropomyosin gene (TPM1) and used to isolate a genomic clone, λTPM1.1, containing part of the TPM1 gene. Fluorescence in situ hybridization of this clone to metaphase chromosome spreads localised TPM1 to chromosome band 15q22. This localisation in humans is consistent with that recently described for the mouse.H Eyre, P A Akkari, S D Wilton, D C Callen, E Baker, N G Lain
Reply to the letter to the editor by Partington and turner - 'Wolf- Hirschhorn and Pitt-Rogers-Danks syndromes'
No full textTracy J. Wright, Michael R. Altherr, David Callen, Kurt Hirschhor
- …
